In recent cardiovascular outcome trials (CVOT), sodium–glucose cotransporter-2 (SGLT-2) inhibitors demonstrated robust results in the reduction of cardiovascular events and hospitalizations for HF [43,44]; currently, along with metformin, SGLT-2 inhibitors are indicated as the first-line pharmacological approach for diabetes in heart failure [45]. Here, SLC5A2 is linked to hydrops fetalis.